ZSB BMO Short Term Bond Index ETF

Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) is pleased to inform about several significant corporate changes currently in preparation:

Now that Sirona Biochem has closed an exclusive global licencing agreement with Allergan Aesthetics, the next steps for sustainable and rapid growth of the company are initiated.

The Board has begun a strategic review of every facet of the company including management, organizational structure, project pipeline, financial position and the exchanges on which the Sirona shares are listed.

Organizational changes and management expansion will occur in both, our headquarters in Vancouver, Canada and our research facility in Rouen, France. External resources will be engaged to assist and there will be updates communicated throughout the remainder of 2022.

Sirona Biochem will ramp-up and accelerate the pipeline development in France. Our science team and CSO, Dr. Geraldine Deliencourt-Godefroy, have a backlog of projects underway and further potential projects that our technology can be applied to. Expertise will be brought in to conduct a review of the lab with the goal to maximize our talent and improve speed to market. We are already in advanced discussions with an experienced expert from the pharmaceutical industry.

We will increase our presence on several fronts. We will seek institutional analysis and investment in Canada, USA and EU and improve our visibility to our current investors. We will also expand our presence in the biotech community to bring in new partnerships through attendance at industry events, improved marketing materials and an overhaul of our professional company image.

Up listing remains a goal of Sirona and we are actively taking steps to achieve the necessary requirements. The changes we are implementing, and the value increase we will achieve, will help meet these requirements.

Sirona Biochem will provide continuous information on the measures implemented.

About Sirona Biochem Corp.Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.

For more information regarding this press release, please contact:

Investor Enquiries:Jonathan WilliamsManaging DirectorMomentum PRPhone:  1.450.332.6939Email: jwilliams@momentumpr.com        

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise.  Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.